In the war against solid tumors arsenic trioxide needs partners

Pochi R. Subbarayan, Bach Ardalan

Research output: Contribution to journalReview articlepeer-review

37 Scopus citations


In the past decade, the therapeutic potential of arsenic trioxide (ATO) in the treatment of acute promyelocytic leukemia (APL) was recognized. This encouraged other investigators to test the efficacy of ATO in the management of other hematological and solid tumor malignancies. Notably, as a single agent, arsenic trioxide did not benefit patients diagnosed with solid tumors. However, when it was combined with other agents, treatment benefit emerged. In this article, we have summarized the outcome of clinical trials that used arsenic trioxide as a single agent as well as in combination settings in patients diagnosed with solid tumors. We have also reviewed possible additional mechanisms by which ATO may be useful as a chemosensitizer in combination therapy. We hope that our review will encourage clinical investigators to rationally combine ATO with additional chemotherapeutic agents in treating patients diagnosed with solid tumors.

Original languageEnglish (US)
Pages (from-to)363-371
Number of pages9
JournalJournal of gastrointestinal cancer
Issue number3
StatePublished - Sep 1 2014

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology


Dive into the research topics of 'In the war against solid tumors arsenic trioxide needs partners'. Together they form a unique fingerprint.

Cite this